Targeting interferon-alpha to dendritic cells enhances a CD8 T cell response to a human CD40-targeted cancer vaccine.

Citation data:

Vaccine, ISSN: 1873-2518, Vol: 35, Issue: 35 Pt B, Page: 4532-4539

Publication Year:
2017
Usage 21
Abstract Views 19
Link-outs 2
Captures 14
Readers 14
Social Media 4
Tweets 4
Citations 1
Citation Indexes 1
Repository URL:
https://mouseion.jax.org/stfb2017/170
PMID:
28743486
DOI:
10.1016/j.vaccine.2017.07.032
Author(s):
Graham, John P; Authie, Pierre; Karolina Palucka, A; Zurawski, Gerard
Publisher(s):
Elsevier BV; Elsevier Science
Tags:
Biochemistry, Genetics and Molecular Biology; Immunology and Microbiology; Veterinary; Medicine; Life Sciences; Medicine and Health Sciences
Most Recent Tweet View All Tweets
article description
Targeting antigens to antigen presenting cells (APC) enhances the potency of recombinant protein CD8 T cell vaccines. Recent comparisons of recombinant protein-based dendritic cell (DC) targeting vaccines revealed differences in cross-presentation and identified CD40 as a potent human DC receptor target for antigen cross-presentation. Contrary to in vitro-derived monocyte (mo)DC, we found that interferon-alpha (IFNα) stimulation of human blood-derived DC was necessary for an antigen-specific IFNγ CD8 T cell response to a CD40 targeted cancer vaccine. Importantly, targeting an adjuvant in the form of IFNα to DC increased their potency to elicit antigen-specific production of IFNγ by CD8 T cells. Thus, we introduce the concept of DC adjuvant targeting to enhance the potency of vaccination.